3-Isopentyl-tetrahydro-furan | 102653-28-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧戊环
• 英文名称: 3-Isopentyl-tetrahydro-furan
• 英文别名: 3-(3-Methylbutyl)oxolane
• CAS: 102653-28-1
• 化学式: C₉H₁₈O
• 分子量: 142.241
• InChiKey: AAADXDWZCKESGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 对甲苯磺酸 作用下， 生成 3-Isopentyl-tetrahydro-furan
  参考文献：
  名称：

  Jur'ew et al., Zhurnal Obshchei Khimii, 1956, vol. 26, p. 553,556; engl. Ausg. S. 593, 595

  摘要：

  DOI：

文献信息

• [EN] QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2015120049A1

  公开（公告）日：2015-08-13

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公开了作为成纤维细胞生长因子抑制剂（FGFR）的化合物，因此可用于治疗可以通过抑制FGFR治疗的疾病。还公开了含有此类化合物的药物组合物以及制备此类化合物的过程。
• QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
  申请人：Principia Biopharma, Inc.

  公开号：US20160200725A1

  公开（公告）日：2016-07-14

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明公开了一种纤维母细胞生长因子抑制剂（FGFR），因此对于通过抑制FGFR可治疗的疾病具有用处的化合物。同时还公开了包含这种化合物的制药组合物以及制备这种化合物的方法。
• Quinolone derivatives as fibroblast growth factor receptor inhibitors
  申请人：Principia Biopharma, Inc.

  公开号：US10294223B2

  公开（公告）日：2019-05-21

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明公开了成纤维细胞生长因子抑制剂（FGFR），因此可用于治疗可通过抑制 FGFR 治疗的疾病的化合物。还公开了含有此类化合物的药物组合物和制备此类化合物的工艺。
• Indole and azaindole inhibitors of pad enzymes
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11524959B1

  公开（公告）日：2022-12-13

  The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, wherein each of Ring A, L, Q, R1, R2, R3, R4, R7, and R8 along with other variables are as defined herein.

  本发明提供了用作 PAD4 抑制剂的式 (I) 化合物、其组合物以及治疗 PAD4 相关疾病的方法，其中环 A、L、Q、R1、R2、R3、R4、R7 和 R8 中的每一个以及其他变量如本文所定义。
• ERK INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170266167A1

  公开（公告）日：2017-09-21

  The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.